A Fresh Perspective on Dosing for Biologic Agents
We are excited to announce the publication of “Getting the Dose Right” – Revisiting the Topic with Focus on Biologic Agents in the Clinical Pharmacology & Therapeutics Journal, co-authored by Baysient’s founder and Chief Science Officer, Diane R. Mould, and Baysient’s Director of Research, Richard N. Upton. This review revisits critical aspects of biologic agents’ dosing, a discussion first sparked by the seminal Peck and Cross article nearly two decades ago.
Today, while advancements have been noted in drug safety and labeling, challenges remain in optimizing treatment with monoclonal antibodies, especially concerning cost, adverse events, and treatment efficacy in varying disease states. The review advocates for innovative approaches such as alternative dosing strategies and therapeutic drug monitoring to enhance clinical outcomes and reduce the incidence of anti-drug antibodies.
